SOURCE: Helix BioPharma Corp.

Helix BioPharma Corp.

December 09, 2016 20:10 ET

Helix BioPharma Corp. to Present at the Biotech Showcase Conference During the Annual JP Morgan Week in San Franscisco

TORONTO, ON--(Marketwired - Dec 9, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, intends to meet a selection of Big Pharma and Big Biotech companies during the Annual JP Morgan Conference week in San Francisco during January 9-12, 2017.

In addition, Helix has been selected to present at the Biotech Showcase Conference on Tuesday, January 10, 2016 at 9:30am at Hilton San Francisco Union Square, which runs in parallel to the JP Morgan Conference. The Biotech Showcase Conference is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

"The timing is perfect" says Anton Gueth, Managing Director of Evolution Life Science Partners, who coordinates and fosters Helix's business development activities, "Helix has generated a lot of brand-new clinical data with their unique Tumour Defence Breaker."

"Our DOS47's proposed mechanism of action suggests that nearly all immuno-oncology therapies, especially checkpoint inhibitors and CAR-T, may strongly benefit from a combination approach with our Tumour Defence Breaker (DOS47) as well as classical chemotherapeutics, e.g. carboplatin" outlined Dr. Sven Rohmann, Helix's Chief Executive Officer.

About L-DOS47
L-DOS47 is Helix's first immunoconjugate-based drug candidate in development is based on Helix's novel DOS47 technology platform which the Company believes alters the tumor microenvironment from acidic to alkaline and is positioning its core technology in the field of immuno-oncology as a unique Tumour Defence Breaker. The Company believes L-DOS47 represents an innovative approach in modifying the microenvironmental conditions of cancer cells which the Company also believes serves as a general defense against cancer drugs and immunotherapies. Breaking the tumor defense by changing the tumor micro environment from acidic to alkaline represents one of the forgotten hallmarks of cancer. L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer. L-DOS47 is currently being evaluated in two clinical studies, one in the United States ("LDOS001") and the other in Poland ("LDOS002").

About LDOS001
LDOS001 is a Phase I, open label, dose escalation study being conducted in the United States at three centers; The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin. The study will also evaluate the potential clinical benefit of L-DOS47 with this combination. Other exploratory objectives include the evaluation of the L-DOS47 pharmacokinetics and immunogenicity.

About LDOS002
LDOS002 is an open-label Phase I/II clinical study being conducted in Poland to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study is being conducted at five Polish centers under the direction of Dr. Dariusz Kowalski at The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology as the overall coordinating investigator, together with four other principal investigators: Prof. Cezary Szczylik, MD, PhD at the Military Medical Institute, Prof. Elzbieta Wiatr, MD, PhD at the National Tuberculosis and Lung Diseases Research Institute, Dr. Aleksandra Szczensa, MD, PhD at the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock and Prof. Rodryg Ramlau, MD, PhD at the Department of Oncology, Poznan University of Medical Science.

About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Cautionary Statements
This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to Helix's operations and strategy, its research and development activities and statements regarding Tumour Defense Breaker, which may be identified by words including, without limitation, "unique", "believes", "will", "should", "may", "expects", "anticipates", "intends", "build", "effective", "continuing" and other similar expressions, are intended to provide information about management's current plans and expectations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, risks inherent in Helix's research and development activities and those risks and uncertainties affecting the Company, as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors, estimates or assumptions have been applied in making forward-looking statements, including, without limitation, the safety and efficacy of L-DOS47; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support and that the factors described in the Helix Risk Factors will not cause the Company's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

Contact Information

  • Investor Relations
    Helix BioPharma Corp.
    21 St. Clair Avenue East, Suite 1100
    Toronto, Ontario, M4T 1L9
    Tel: 416 925-3232
    Email: ir@helixbiopharma.com